Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 435

1.

The vacuole guard hypothesis: how intravacuolar pathogens fight to maintain the integrity of their beloved home.

Anand I, Choi W, Isberg RR.

Curr Opin Microbiol. 2020 Feb 7;54:51-58. doi: 10.1016/j.mib.2020.01.008. [Epub ahead of print] Review.

PMID:
32044688
2.

Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients.

Bilchick KC, Wang Y, Curtis JP, Cheng A, Dharmarajan K, Shadman R, Dardas TF, Anand I, Lund LH, Dahlström U, Sartipy U, Maggioni A, O'Connor C, Levy WC.

Am Heart J. 2019 Dec 27;222:93-104. doi: 10.1016/j.ahj.2019.12.017. [Epub ahead of print]

PMID:
32032927
3.

Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF.

Anand IS, Konstam MA, Klein HU, Mann DL, Ardell JL, Gregory DD, Massaro JM, Libbus I, DiCarlo LA, Udelson JJE, Butler J, Parker JD, Teerlink JR.

ESC Heart Fail. 2020 Jan 27. doi: 10.1002/ehf2.12592. [Epub ahead of print]

4.

Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.

Myhre PL, Vaduganathan M, O'Meara E, Claggett BL, de Denus S, Jarolim P, Anand IS, Pitt B, Rouleau JL, Solomon SD, Pfeffer MA, Desai AS.

Circ Heart Fail. 2020 Jan;13(1):e006638. doi: 10.1161/CIRCHEARTFAILURE.119.006638. Epub 2020 Jan 20.

PMID:
31957468
5.

Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T.

Aimo A, Januzzi JL Jr, Vergaro G, Richards AM, Lam CSP, Latini R, Anand IS, Cohn JN, Ueland T, Gullestad L, Aukrust P, Brunner-La Rocca HP, Bayes-Genis A, Lupón J, de Boer RA, Takeishi Y, Egstrup M, Gustafsson I, Gaggin HK, Eggers KM, Huber K, Gamble GD, Ling LH, Leong KTG, Yeo PSD, Ong HY, Jaufeerally F, Ng TP, Troughton R, Doughty RN, Passino C, Emdin M.

Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1701. [Epub ahead of print]

PMID:
31919929
6.

How I treat Anemia in Heart Failure.

Anand I, Gupta P.

Blood. 2020 Jan 2. pii: blood.2019004004. doi: 10.1182/blood.2019004004. [Epub ahead of print]

PMID:
31895946
7.

Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN-HF Registry.

MacDonald MR, Tay WT, Teng TK, Anand I, Ling LH, Yap J, Tromp J, Wander GS, Naik A, Ngarmukos T, Siswanto BB, Hung CL, Richards AM, Lam CSP; ASIAN‐F investigators †; ASIAN‐F investigators <xref ref-type="author-note" rid="jah34461-note-1001"><sup>†</sup></xref>.

J Am Heart Assoc. 2020 Jan 7;9(1):e012199. doi: 10.1161/JAHA.119.012199. Epub 2019 Dec 19.

8.

Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN-HF registry.

Beusekamp JC, Teng TK, Tay WT, Ouwerkerk W, Richards AM, Anand IS, Chopra VK, Wander GS, van der Meer P, Voors AA, Lam CSP, Tromp J.

Eur J Heart Fail. 2019 Dec 18. doi: 10.1002/ejhf.1640. [Epub ahead of print] No abstract available.

PMID:
31851416
9.

Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction.

Teng TK, Cooper L, Tay WT, Luo N, Sharma A, Whellan D, Anand I, Pina IL, Tromp J, Richards AM, Kraus WE, Connor CMO, Mentz RJ, Lam CSP.

Eur J Heart Fail. 2019 Dec 18. doi: 10.1002/ejhf.1648. [Epub ahead of print] No abstract available.

PMID:
31849161
10.

Sex-Related Differences in Heart Failure With Preserved Ejection Fraction.

Dewan P, Rørth R, Raparelli V, Campbell RT, Shen L, Jhund PS, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Køber L, Komajda M, McKelvie RS, O'Meara E, Pfeffer MA, Pitt B, Solomon SD, Swedberg K, Zile MR, McMurray JJV.

Circ Heart Fail. 2019 Dec;12(12):e006539. doi: 10.1161/CIRCHEARTFAILURE.119.006539. Epub 2019 Dec 9.

PMID:
31813280
11.

Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.

Vardeny O, Claggett B, Vaduganathan M, Beldhuis I, Rouleau J, O'Meara E, Anand IS, Shah SJ, Sweitzer NK, Fang JC, Desai AS, Lewis EF, Pitt B, Pfeffer MA, Solomon SD; TOPCAT Investigators.

JACC Heart Fail. 2019 Dec;7(12):1022-1028. doi: 10.1016/j.jchf.2019.08.019.

PMID:
31779923
12.

GER characteristics after fundoplication in children with aerodigestive disorders.

Anand I, Pentiuk S, Garza J, Su W, Fei L, Kaul A.

J Pediatr Surg. 2019 Nov 22. pii: S0022-3468(19)30589-5. doi: 10.1016/j.jpedsurg.2019.08.049. [Epub ahead of print]

PMID:
31767193
13.

Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.

Solomon SD, Vaduganathan M, L Claggett B, Packer M, Zile M, Swedberg K, Rouleau J, A Pfeffer M, Desai A, H Lund L, Kober L, Anand I, Sweitzer N, Linssen G, Merkely B, Luis Arango J, Vinereanu D, Chen CH, Senni M, Sibulo A, Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJV.

Circulation. 2020 Feb 4;141(5):352-361. doi: 10.1161/CIRCULATIONAHA.119.044586. Epub 2019 Nov 17.

PMID:
31736342
14.

Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.

McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer N, Vardeny O, Claggett B, Jhund PS, Solomon SD.

Circulation. 2020 Feb 4;141(5):338-351. doi: 10.1161/CIRCULATIONAHA.119.044491. Epub 2019 Nov 17.

PMID:
31736337
15.

Atrial Fibrillation in the Elderly: The Role of Sub-Clinical Isolated Cardiac Amyloidosis.

Krishnappa D, Dykoski R, Can I, Mbai M, Anand IS, Florea V, Chandrashekar YS, Li JM, Tholakanahalli VN.

Sci Rep. 2019 Nov 12;9(1):16584. doi: 10.1038/s41598-019-53119-z.

16.

Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial.

Ramalho SHR, Claggett BL, Sweitzer NK, Fang JC, Shah SJ, Anand IS, Pitt B, Lewis EF, Pfeffer MA, Solomon SD, Shah AM.

Eur J Heart Fail. 2019 Oct 31. doi: 10.1002/ejhf.1593. [Epub ahead of print] No abstract available.

PMID:
31667977
17.

Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study.

Chandramouli C, Tay WT, Bamadhaj NS, Tromp J, Teng TK, Yap JJL, MacDonald MR, Hung CL, Streng K, Naik A, Wander GS, Sawhney J, Ling LH, Richards AM, Anand I, Voors AA, Lam CSP; ASIAN-HF Investigators.

PLoS Med. 2019 Sep 24;16(9):e1002916. doi: 10.1371/journal.pmed.1002916. eCollection 2019 Sep.

18.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators.

N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.

PMID:
31535829
19.

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees.

N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.

PMID:
31475794
20.

Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction.

Yap J, Tay WT, Teng TK, Anand I, Richards AM, Ling LH, MacDonald MR, Chandramouli C, Tromp J, Siswanto BB; ASIAN‐HF (Asian Sudden Cardiac Death in Heart Failure) Registry Investigators, Zile M, McMurray J, Lam CSP.

J Am Heart Assoc. 2019 Sep 3;8(17):e013114. doi: 10.1161/JAHA.119.013114. Epub 2019 Aug 21.

21.

Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.

Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Køber L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV.

J Am Coll Cardiol. 2019 Aug 6;74(5):601-612. doi: 10.1016/j.jacc.2019.05.052.

PMID:
31370950
22.

Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.

Premchand RK, Sharma K, Mittal S, Monteiro R, Libbus I, Ardell JL, Gregory DD, KenKnight BH, Amurthur B, DiCarlo LA, Anand IS.

ESC Heart Fail. 2019 Oct;6(5):1052-1056. doi: 10.1002/ehf2.12484. Epub 2019 Jul 24.

23.

Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial.

Myhre PL, Vaduganathan M, Claggett BL, Lam CSP, Desai AS, Anand IS, Sweitzer NK, Fang JC, O'Meara E, Shah SJ, Shah AM, Lewis EF, Rouleau J, Pitt B, Solomon SD.

Eur J Heart Fail. 2019 Oct;21(10):1288-1291. doi: 10.1002/ejhf.1542. Epub 2019 Jul 22. No abstract available.

PMID:
31332920
24.

Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction.

Minamisawa M, Seidelmann SB, Claggett B, Hegde SM, Shah AM, Desai AS, Lewis EF, Shah SJ, Sweitzer NK, Fang JC, Anand IS, O'Meara E, Rouleau JL, Pitt B, Solomon SD.

JACC Heart Fail. 2019 Aug;7(8):664-675. doi: 10.1016/j.jchf.2019.04.020. Epub 2019 Jul 10.

PMID:
31302049
25.

Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.

Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W, Lefkowitz MP, Shi VC, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV, Solomon SD; PARAGON-HF Investigators.

JACC Heart Fail. 2019 Oct;7(10):862-874. doi: 10.1016/j.jchf.2019.05.015. Epub 2019 Jul 10.

PMID:
31302043
26.

Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction.

Tromp J, Lim SL, Tay WT, Teng TK, Chandramouli C, Ouwerkerk W, Wander GS, Sawhney JPS, Yap J, MacDonald MR, Ling LH, Sattar N, McMurray JJV, Richards AM, Anand I, Lam CSP; ASIAN-HF Investigators.

Diabetes Care. 2019 Sep;42(9):1792-1799. doi: 10.2337/dc18-2515. Epub 2019 Jul 10.

PMID:
31292141
27.

Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction.

Shen L, Rørth R, Cosmi D, Kristensen SL, Petrie MC, Cosmi F, Latini R, Køber L, Anand IS, Carson PE, Granger CB, Komajda M, McKelvie RS, Solomon SD, Staszewsky L, Swedberg K, Huynh T, Zile MR, Jhund PS, McMurray JJV.

Eur J Heart Fail. 2019 Aug;21(8):974-984. doi: 10.1002/ejhf.1535. Epub 2019 Jul 4.

PMID:
31271255
28.

Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction.

Selvaraj S, Claggett B, Shah SJ, Anand IS, Rouleau JL, Desai AS, Lewis EF, Vaduganathan M, Wang SY, Pitt B, Sweitzer NK, Pfeffer MA, Solomon SD.

Circ Heart Fail. 2019 Jul;12(7):e006125. doi: 10.1161/CIRCHEARTFAILURE.119.006125. Epub 2019 Jun 21.

PMID:
31220936
29.

Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome.

Aimo A, Januzzi JL Jr, Vergaro G, Clerico A, Latini R, Meessen J, Anand IS, Cohn JN, Gravning J, Ueland T, Nymo SH, Brunner-La Rocca HP, Bayes-Genis A, Lupón J, de Boer RA, Yoshihisa A, Takeishi Y, Egstrup M, Gustafsson I, Gaggin HK, Eggers KM, Huber K, Tentzeris I, Ripoli A, Passino C, Emdin M.

Eur J Prev Cardiol. 2019 Nov;26(16):1751-1759. doi: 10.1177/2047487319852809. Epub 2019 Jun 1.

PMID:
31154828
30.

Nature and prevalence of adverse drug reaction of antiretroviral medications in Halibet National Referral Hospital: a retrospective study.

Hagos L, Fessehaye S, Anand IS.

BMC Pharmacol Toxicol. 2019 May 6;20(1):24. doi: 10.1186/s40360-019-0307-9.

31.

Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial.

Piccini JP, Abraham WT, Dufton C, Carroll IA, Healey JS, van Veldhuisen DJ, Sauer WH, Anand IS, White M, Wilton SB, Aleong R, Rienstra M, Krueger SK, Ayala-Paredes F, Khaykin Y, Merkely B, Miloradović V, Wranicz JK, Ilkhanoff L, Ziegler PD, Davis G, Emery LL, Marshall D, Kao DP, Bristow MR, Connolly SJ; GENETIC-AF Trial Investigators.

JACC Heart Fail. 2019 Jul;7(7):586-598. doi: 10.1016/j.jchf.2019.04.004. Epub 2019 Apr 29.

PMID:
31042551
32.

Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus.

Chia YMF, Teng TK, Tay WT, Anand I, MacDonald MR, Yap J, Chandramouli C, Richards AM, Tromp J, Ouwerkerk W, Ling LH, Lam CSP; ASIAN-HF Investigators.

Eur J Heart Fail. 2019 May;21(5):685-688. doi: 10.1002/ejhf.1467. Epub 2019 Apr 29. No abstract available.

PMID:
31033098
33.

Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.

Shen L, Jhund PS, Docherty KF, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Swedberg K, Zile MR, McMurray JJV.

JACC Heart Fail. 2019 May;7(5):418-427. doi: 10.1016/j.jchf.2018.12.006. Epub 2019 Apr 10.

PMID:
30981744
34.

What Explains the Benefits of ARNI Therapy in Heart Failure?

Anand IS.

J Am Coll Cardiol. 2019 Mar 26;73(11):1285-1287. doi: 10.1016/j.jacc.2019.01.019. No abstract available. Erratum in: J Am Coll Cardiol. 2019 Jun 4;73(21):2789.

PMID:
30898203
35.

N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.

Kristensen SL, Mogensen UM, Jhund PS, Rørth R, Anand IS, Carson PE, Desai AS, Pitt B, Pfeffer MA, Solomon SD, Zile MR, Køber L, McMurray JJV.

Circ Heart Fail. 2019 Mar;12(3):e005766. doi: 10.1161/CIRCHEARTFAILURE.118.005766.

PMID:
30871349
36.

Self-medication with over the counter drugs, prevalence of risky practice and its associated factors in pharmacy outlets of Asmara, Eritrea.

Tesfamariam S, Anand IS, Kaleab G, Berhane S, Woldai B, Habte E, Russom M.

BMC Public Health. 2019 Feb 6;19(1):159. doi: 10.1186/s12889-019-6470-5.

37.

Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study).

Huynh T, Harty BJ, Claggett B, Fleg JL, McKinlay SM, Anand IS, Lewis EF, Joseph J, Desai AS, Sweitzer NK, EileenO'Meara, Pitt B, Pfeffer MA, Rouleau JL.

Am J Cardiol. 2019 Feb 15;123(4):611-617. doi: 10.1016/j.amjcard.2018.11.022. Epub 2018 Nov 24.

38.

Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction.

Myhre PL, O'Meara E, Claggett BL, de Denus S, Jarolim P, Anand IS, Beldhuis IE, Fleg JL, Lewis E, Pitt B, Rouleau JL, Solomon SD, Pfeffer MA, Desai AS.

Circ Heart Fail. 2018 Nov;11(11):e005312. doi: 10.1161/CIRCHEARTFAILURE.118.005312.

PMID:
30571192
39.

Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.

Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, O'Meara E, Desai AS, Lewis EF, Pitt B, Sweitzer NK, Fang JC, Pfeffer MA, Solomon SD.

Circ Heart Fail. 2018 Nov;11(11):e005288. doi: 10.1161/CIRCHEARTFAILURE.118.005288.

40.

Response by Anand and Gupta to Letter Regarding Article, "Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies".

Anand I, Gupta P.

Circulation. 2018 Dec 18;138(25):2976-2977. doi: 10.1161/CIRCULATIONAHA.118.037553. No abstract available.

PMID:
30566014
41.

Heart Failure With Preserved Ejection Fraction in the Young.

Tromp J, MacDonald MR, Tay WT, Teng TK, Hung CL, Narasimhan C, Shimizu W, Ling LH, Ng TP, Yap J, McMurray JJV, Zile MR, Richards AM, Anand IS, Lam CSP.

Circulation. 2018 Dec 11;138(24):2763-2773. doi: 10.1161/CIRCULATIONAHA.118.034720.

PMID:
30565987
42.

Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN-HF registry.

Chandramouli C, Teng TK, Tay WT, Yap J, MacDonald MR, Tromp J, Yan L, Siswanto B, Reyes EB, Ngarmukos T, Yu CM, Hung CL, Anand I, Richards AM, Ling LH, Regensteiner JG, Lam CSP; ASIAN-HF Investigators.

Eur J Heart Fail. 2019 Mar;21(3):297-307. doi: 10.1002/ejhf.1358. Epub 2018 Dec 10.

PMID:
30548089
43.

High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure.

Aimo A, Januzzi JL Jr, Vergaro G, Ripoli A, Latini R, Masson S, Magnoli M, Anand IS, Cohn JN, Tavazzi L, Tognoni G, Gravning J, Ueland T, Nymo SH, Rocca HB, Bayes-Genis A, Lupón J, de Boer RA, Yoshihisa A, Takeishi Y, Egstrup M, Gustafsson I, Gaggin HK, Eggers KM, Huber K, Tentzeris I, Wilson Tang WH, Grodin JL, Passino C, Emdin M.

Int J Cardiol. 2019 Feb 15;277:166-172. doi: 10.1016/j.ijcard.2018.10.079. Epub 2018 Oct 26.

PMID:
30416028
44.

sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.

Emdin M, Aimo A, Vergaro G, Bayes-Genis A, Lupón J, Latini R, Meessen J, Anand IS, Cohn JN, Gravning J, Gullestad L, Broch K, Ueland T, Nymo SH, Brunner-La Rocca HP, de Boer RA, Gaggin HK, Ripoli A, Passino C, Januzzi JL Jr.

J Am Coll Cardiol. 2018 Nov 6;72(19):2309-2320. doi: 10.1016/j.jacc.2018.08.2165.

45.

The biological variation of plasma proenkephalin: data from a stable heart failure cohort.

Wu AHB, Anand I.

Clin Chem Lab Med. 2019 May 27;57(6):e105-e107. doi: 10.1515/cclm-2018-0876. No abstract available.

PMID:
30332388
46.

Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study.

Ueland T, Gullestad L, Kou L, Aukrust P, Anand IS, Broughton MN, McMurray JJ, van Veldhuisen DJ, Warren DJ, Bolstad N.

ESC Heart Fail. 2018 Dec;5(6):1052-1059. doi: 10.1002/ehf2.12312. Epub 2018 Aug 25.

47.

Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.

Myhre PL, Vaduganathan M, Claggett BL, Anand IS, Sweitzer NK, Fang JC, O'Meara E, Shah SJ, Desai AS, Lewis EF, Rouleau J, Pitt B, Pfeffer MA, Solomon SD.

JAMA Cardiol. 2018 Oct 1;3(10):1000-1005. doi: 10.1001/jamacardio.2018.2568.

48.

Heart failure with preserved ejection fraction in Asia.

Tromp J, Teng TH, Tay WT, Hung CL, Narasimhan C, Shimizu W, Park SW, Liew HB, Ngarmukos T, Reyes EB, Siswanto BB, Yu CM, Zhang S, Yap J, MacDonald M, Ling LH, Leineweber K, Richards AM, Zile MR, Anand IS, Lam CSP; ASIAN-HF Investigators.

Eur J Heart Fail. 2019 Jan;21(1):23-36. doi: 10.1002/ejhf.1227. Epub 2018 Aug 16.

49.

Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.

Teng TK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, Wander GS, Yap JJ, MacDonald MR, Xu CF, Chia YM, Shimizu W; ASIAN-HF investigators, Richards AM, Voors A, Lam CS.

Lancet Glob Health. 2018 Sep;6(9):e1008-e1018. doi: 10.1016/S2214-109X(18)30306-1.

50.

T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF.

Abraityte A, Aukrust P, Kou L, Anand IS, Young J, Mcmurray JJV, van Veldhuisen DJ, Gullestad L, Ueland T.

Clin Res Cardiol. 2019 Feb;108(2):133-141. doi: 10.1007/s00392-018-1331-2. Epub 2018 Jul 26.

PMID:
30051179

Supplemental Content

Support Center